Background: The most common treatment of myasthenia gravis is high-dose prednisolone administration and thymectomy. A well-known adverse effect of prednisolone is hyperglycemia, however, to date there is no such detailed report. Patients and Methods: We treated 325 myasthenia gravis patients in a recent 35 years period, and found 11 patients with diabetes mellitus. We compared these 11 diabetic patients with previously-reported cases. Results: These 11 patients did not have any antibody against β-cells in the pancreas such as anti-glutamic acid decarboxylase antibody. In 10 of 11 patients diabetes mellitus was controlled with oral medications. Conclusion: Myasthenic patients with diabetes mellitus could be classified into 2 groups, one group with positive organ-specific autoantibodies to many organs (with type 1 diabetes mellitus), and the other group with diabetes mellitus onset during prednisolone administration (with type 2 diabetes mellitus). © 2007 The Japanese Society of Internal Medicine.
CITATION STYLE
Wakata, N., Nemoto, H., Konno, S., Nakazora, H., Nomoto, N., Sugimoto, H., & Kurihara, T. (2007). Myasthenia gravis and diabetes mellitus: - A 35-year retrospective study. Internal Medicine, 46(9), 557–559. https://doi.org/10.2169/internalmedicine.46.6237
Mendeley helps you to discover research relevant for your work.